- Conditions
- Pulmonary Hypertension
- Interventions
- Riociguat (Adempas, BAY63-2521), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 445 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 402
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Aortic Stenosis, Mitral Regurgitation, Pulmonary Hypertension, Heart Failure, Systolic, Cardiovascular Diseases, Coronary Artery Disease
- Interventions
- MindMics earbud
- Other
- Lead sponsor
- Scripps Health
- Other
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Pulmonary Arterial Hypertension - Lung Perfusion Scans
- Other
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- iloprost
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 32
- States / cities
- La Jolla, California • Sacramento, California • Torrance, California + 28 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- sildenafil citrate
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 11
- States / cities
- Atlanta, Georgia • Grand Rapids, Michigan • Wooster, Ohio + 2 more
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
- Interventions
- Ralinepag, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 687 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
- Conditions
- Coronary Artery Disease, Cerebral Vascular Disease, Peripheral Artery Disease, Renal Insufficiency, Diabetes, COPD, Hypertension, Active Smoker, Cancer, CHF, Prior DVT/PE
- Interventions
- Not listed
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 21 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Caridovascular Disease, Congenital Heart Disease, Pulmonary Hypertension
- Interventions
- Cardiac Real-time MRI RHC (Right Heart Catheterization)
- Procedure
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 2 Years to 99 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- UT-15C SR, Tyvaso Inhalation Solution
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Rochester, Minnesota • St Louis, Missouri + 3 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- ACT-293987
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 709 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 45
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- imatinib mesylate, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
- Conditions
- Healthy Volunteers, Pulmonary Arterial Hypertension
- Interventions
- LTP, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 232 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Orange, California • Stanford, California + 16 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Carvedilol
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Pulmonary Arterial Hypertension, Renal Dysfunction
- Interventions
- UT-15C SR (treprostinil diethanolamine)
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- (-)-Epicatechin
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Noninvasive actigraphy monitor
- Other
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Nitric Oxide
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Selexipag, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 43
- States / cities
- Mobile, Alabama • Tucson, Arizona • La Jolla, California + 32 more
- Conditions
- Asthma, Atrial Fibrillation, Chronic Obstructive Pulmonary Disease, Coronary Artery Disease, Congestive Heart Failure, Hyperlipidemia, Hypertension, Myocardial Infarction, Sickle Cell Disease, Sleep Apnea, Smoking, Stroke, Tuberculosis
- Interventions
- Problem List Suggestion
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,386 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2016
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Portland, Oregon • Camp Hill, Pennsylvania + 1 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Iloprost Inhalation Solution (Ventavis)
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 3 Years to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 2
- States / cities
- Denver, Colorado • New York, New York
- Conditions
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
- Interventions
- FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg, Placebo FDC, Placebo macitentan, Placebo tadalafil
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 26
- States / cities
- Fullerton, California • Los Angeles, California • Atlanta, Georgia + 22 more
- Conditions
- Hypertension, Pulmonary
- Interventions
- Tadalafil, Placebo, ERA as specific PAH treatment
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Detroit, Michigan • Cincinnati, Ohio + 4 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Imatinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Mineola, New York
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, PAH WHO Group I
- Interventions
- Sitaxsentan, Bosentan, Ambrisentan
- Drug
- Lead sponsor
- West Penn Allegheny Health System
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania